SCHEMBL5136089

SCHEMBL5136089

CCCCN(Cc1ccc(C)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CC

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 2/20 0.43
C5AR1 P21730 1/20 0.41
NLRP3 Q96P20 1/20 0.40
TP53 P04637 1/20 0.39
ATP4A P20648 3/20 0.39
ATP4B P51164 3/20 0.39
BCHE P06276 1/20 0.38
HDAC1 Q13547 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.36
HSD11B1 P28845 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135903 0.93 C5AR1 (0.41) CRHR1C5AR1ATP4AATP4BBCHE
SCHEMBL5070130 0.92 C5AR1 (0.47) CRHR1C5AR1TP53ATP4AATP4B
SCHEMBL5135599 0.92 C5AR1 (0.43) CRHR1C5AR1TP53ATP4AATP4B
SCHEMBL5075018 0.89 CRHR1 (0.40) CRHR1C5AR1TP53ATP4AATP4B
SCHEMBL5135000 0.89 ATP4A (0.47) ATP4AATP4BBCHE
SCHEMBL5136173 0.88 C5AR1 (0.47) CRHR1C5AR1TP53TSHRHSD11B1
SCHEMBL5134667 0.87 C5AR1 (0.43) CRHR1C5AR1BCHEMAPTTSHR
SCHEMBL5137489 0.87 C5AR1 (0.48) CRHR1C5AR1ATP4AATP4BTSHR
SCHEMBL649161 0.86 C5AR1 (0.47) CRHR1C5AR1ATP4AATP4BBCHE
SCHEMBL5134816 0.86 CRHR1 (0.44) CRHR1C5AR1ATP4AATP4BBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed